



## Anti-Osteoporotic Effects of Kukoamine B Isolated from *Lycii Radicis* Cortex Extract on Osteoblast and Osteoclast Cells and Ovariectomized Osteoporosis Model Mice


Eunkuk Park, Jeonghyun Kim, Mun-Chang Kim, Subin Yeo, Jieun Kim, Seulbi Park, Miran Jo, Chun Whan Choi, Hyun-Seok Jin, Sang Woo Lee, Wan Yi Li, Ji-Won Lee, Jin-Hyok Park, Dam Huh and Seon-Yong Jeong




**Figure S1.** Fractionation and isolation of the bioactive component enhancing osteoblast differentiation from 30% ethanol extract of *Lycii radidis* cortex.




**Figure S2.** ALP activity test of the fractions isolated in Figure S1 using the pre-osteoblast MC3T3-E1 cells. Cells were treated with ascorbic acid (50  $\mu\text{g}/\text{ml}$ ) and  $\beta$ -glycerophosphate (10 mM) and cultured with three different concentrations (1, 5, and 10 mg), and an ALP activity was assessed. Control: non-treated cells. \*:  $p < 0.05$  vs. control.




**Figure S3.** Results of proton nuclear magnetic resonance ( $^1\text{H-NMR}$ ), (A) Carbon-13 nuclear magnetic resonance ( $^{13}\text{C-NMR}$ ), (B) mass spectrum, and (C) analyses of the B4 fraction of Supplementary Fig. S1.




**Figure S4.** Effects of kukoamine B (KB) on alkaline phosphatase (ALP) activity in preosteoblast MC3T3-E1 cells. Cells were treated with ascorbic acid (50  $\mu\text{g}/\text{ml}$ ) and  $\beta$ -glycerophosphate (10 mM) and cultured with three different concentrations of KB (5, 10, and 20  $\mu\text{M}$ ), and an ALP activity assay was done at 2, 3, 4, and 5 days of incubation. Control: KB non-treated cells. \*:  $p < 0.05$  vs. control.



**Figure S5.** Effects of kukoamine B (KB) on cell viability of primary-cultured monocytes. After induction of osteoclast differentiation by treatment of 30 ng/ml of M-CSF and 50 ng/ml of RANKL (Induction), cells were co-treated with three different concentrations of KB (5, 10, and 20  $\mu$ M) for 6 days, and then cell viability was assessed.



**Figure S6.** Effects of kukoamine B (KB) on osteoclast differentiation of primary-cultured monocytes. After induction of osteoclast differentiation by treatment of 30 ng/ml of M-CSF and 50 ng/ml of RANKL (Induction), cells were co-treated with three different concentrations of KB (5, 10, and 20  $\mu$ M) for 3 and 6 days, and tartrate-resistant acid phosphatase (TRAP) activity was assessed. \*:  $p < 0.05$  vs. Induction.



**Figure S7.** Effects of kukoamine B (KB) on osteoblast and osteoclast differentiations in the co-culture of pre-osteoblasts and primary monocytes. Co-cultured MC3T3-E1 and primary monocyte cells were treated with osteoblast differentiation reagents, 50  $\mu\text{g}/\text{mL}$  of ascorbic acid, and 10 mM of  $\beta$ -glycerophosphate and then co-treated with three different concentrations of KB (5, 10, and 20  $\mu\text{M}$ ) for 3 and 6 days. Alkaline phosphatase (ALP) activity (A) and tartrate-resistant acid phosphatase (TRAP) activity (B) were assessed in the co-culture cells. Control: KB non-treated cells. \*:  $p < 0.05$  vs. Control.